By Nicholas G. Miller
Shares of Medpace soared after the company's second-quarter earnings and revenue surpassed expectations.
The stock was up 53% to $472.63 in Tuesday's session and is now up 42% on the year.
The Cincinnati clinical-research company late Monday reported $3.10 in earnings per share and $603.3 million in revenue, beating analysts' expectations of a $2.98 per-share profit and $538.8 million in sales.
In its earnings call Tuesday, the company said it benefited from decreased cancellations as well as from a shifting away from oncology research and toward clinical trials in areas such as metabolic studies, which it said results in faster revenue and more reimbursable costs.
Chief Executive August Troendle also said that even amid concerns about a broad decline in funding for biotech research, its clients with ongoing studies "were able to obtain sufficient funding to keep the trials running."
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
July 22, 2025 12:57 ET (16:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。